Global Benign Prostatic Hyperplasia Treatment
Market Report
2024
Benign Prostatic Hyperplasia Treatment Market Report 2024 (Global Edition)
Benign Prostatic Hyperplasia Treatment's total global market size was $6.27 Billion in 2022 whereas it will rise to $8.79 Billion with the Compound Average Growth Rate of 4.94% (2023 to 2030).
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Benign Prostatic Hyperplasia Treatment Market Report 2024.
Global Benign Prostatic Hyperplasia Treatment Market Report 2024 Market Size Split by Type (Drug Class, Minimally Invasive Surgeries, Laser Therapy, Others), by Application (Hospitals, Ambulatory Surg...
Global Benign Prostatic Hyperplasia Treatment's market size was $6.27 Billion in 2022 whereas it will rise to $8.79 Billion with the Compound Average Growth Rate of 4.94% (2023 to 2030).
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Benign Prostatic Hyperplasia Treatment Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 4.94% |
| Market Split by Type |
|
| Market Split by Application |
|
| Market Split by Drug Treatment |
|
| Market Split by End-Use |
|
| Market Split by Surgical Treatment |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Benign Prostatic Hyperplasia Treatment industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Benign Prostatic Hyperplasia Treatment Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Benign Prostatic Hyperplasia Treatment Market Report Description
Introduction of Benign Prostatic Hyperplasia Treatment
Benign prostatic hyperplasia (BPH) is also called prostate enlargement which is a non-malignant enlargement of the prostate gland. It is the most common benign tumor seen in men and it begins at the age of 25 and increases with age. Prostate-specific antigen (PSA) blood test is carried out to diagnose prostate cancer. The rise in the prevalence of benign prostatic hyperplasia and the surge in demand for the treatment are the factors driving the market growth for benign prostatic hyperplasia treatment.
Factors Affecting Benign Prostatic Hyperplasia Treatment Market Growth
-
Rising prevalence of benign prostatic hyperplasia and increasing geriatric population will drive the market
The rise in prevalence of benign prostatic hyperplasia is the major factor driving the benign prostatic hyperplasia treatment market. In addition, hormonal changes, change in endocrine status, and increased inflammatory response cause enlargement of the prostate gland leading to BPH.
The increasing geriatric population is another driving factor for the benign prostatic hyperplasia treatment market. In the report of the World Health Organization, the geriatric population is going to reach 2 billion by the year 2050. The geriatric population is predicted to grow fast in developed nations. Geriatric population is more prone to developing BPH and other chronic diseases thus it is anticipated to propel the benign prostatic hyperplasia treatment market.
Restraining Factor of Benign Prostatic Hyperplasia Treatment
-
Side effects associated with drug treatment will limit the market growth:
Drugs used for the treatment of BPH include alpha-blockers, and 5-alpha-reductase inhibitors (5-ARIs) may cause dizziness, rhinitis, gynecomastia, and orthostatic hypotension. Orthostatic hypotension and dizziness can cause significant morbidities like falls and injuries to elderly persons. However, the rising preference for minimally invasive surgeries is propelling the benign prostatic hyperplasia treatment market.
Impact of the COVID-19 Pandemic on the Benign Prostatic Hyperplasia Treatment Market:
The outbreak of COVID-19 impacted negatively the benign prostatic hyperplasia treatment market. The lockdown restrictions led to disruption in manufacturing and transportation. Factors like fewer hospital visits, limited availability of medical facilities, and shortage of staff resulted in a negative impact on the market.
We have various report editions of Benign Prostatic Hyperplasia Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Benign Prostatic Hyperplasia Treatment Market Insights Video
Benign Prostatic Hyperplasia Treatment Market News
-
In the third quarter of 2022
Boston Scientific launched Rezum water vapour therapy system, a single-use digital flexible ureteroscope system. In the first quarter of 2023, Boston Scientific received FDA clearance for the Rezum system.
-
In 2017, Teleflex completed two acquisitions of NeoTract and Vascular Solutions.
NeoTract was a medical device company that launched the UroLift system. In April 2022, Teleflex launched the Urolift System in Japan for the treatment of benign prostatic hyperplasia (BPH).
Top Companies Market Share in Benign Prostatic Hyperplasia Treatment Industry: (In no particular order of Rank)
- Abbott
- Astellas Pharma Inc
- Allergan plc
- GlaxoSmithKline plc
- Eli Lilly
- Boehringer Ingelheim GmbH
- Asahi Kasei Corporation
- Pfizer Inc
- Boston Scientific Corporation
- Sanofi
- Merck & Co Inc
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC
- Teleflex Incorporated
- Endo International plc
- Olympus Corporation
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
The North America segment is the leading segment of the Benign Prostatic Hyperplasia Treatment market
The benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East, and Africa. The North America segment is the leading segment of the market owing to the high prevalence of BPH in the region, advanced healthcare infrastructure, and rapidly ageing population in the North America region. For instance, as per an article published by Elsevier Ltd., 5.19 million cases of BPH were registered in the North America region in 2019. The rapidly ageing population coupled with diabetes and other health-related issues will drive the occurrence of benign prostatic hyperplasia. Thus, the need for benign prostatic hyperplasia treatment will increase in the near future.
The current report Scope analyzes Benign Prostatic Hyperplasia Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Benign Prostatic Hyperplasia Treatment Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Benign Prostatic Hyperplasia Treatment Market Analysis
Global Benign Prostatic Hyperplasia Treatment Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Benign Prostatic Hyperplasia Treatment Industry growth. Benign Prostatic Hyperplasia Treatment market has been segmented with the help of its Type, Application Drug Treatment, and others. Benign Prostatic Hyperplasia Treatment market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Type Segment Analysis of Benign Prostatic Hyperplasia Treatment Market
Based on present and future trends, the market size is estimated from 2019 to 2031. Moreover, study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest growing type segment for Benign Prostatic Hyperplasia Treatment market.
Type of Benign Prostatic Hyperplasia Treatment analyzed in this report are as follows:
- Drug Class
- Minimally Invasive Surgeries
- Laser Therapy
- Others
Benign Prostatic Hyperplasia Treatment Market Share (%) by Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Benign Prostatic Hyperplasia Treatment Industry. Request a Free Sample PDF!
Application Segment Analysis of Benign Prostatic Hyperplasia Treatment Market
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities for each application of Benign Prostatic Hyperplasia Treatment from 2019 to 2031. This will also help to analyze the demand for Benign Prostatic Hyperplasia Treatment across different end-use industries. Our research team will also help acquire additional data such as Value Chain, Patent analysis, Company Evaluation Quadrant (Matrix), and much more confidential analysis and data insights.
Some of the key Application of Benign Prostatic Hyperplasia Treatment are:
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Others
Benign Prostatic Hyperplasia Treatment Market Share (%) by Application in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Benign Prostatic Hyperplasia Treatment Drug Treatment Segment Analysis
- Alpha-blockers
- 5-Alpha-reductase Inhibitor (5-ARIs)
- Others
Benign Prostatic Hyperplasia Treatment End-Use Segment Analysis
Benign Prostatic Hyperplasia Treatment Market, by End-Use
On the benign prostatic hyperplasia treatment market is segmented into hospitals, home healthcare, ambulatory surgical centers, specialty clinics, and others. The home healthcare segment accounts for the largest share of the market because most patients are recommended drugs instead of surgeries. Patients are also asked to take prescribed drugs after surgery, henceforth home healthcare segment is the leading segment of the benign prostatic hyperplasia treatment market.
- Hospitals
- Home Healthcare
- Ambulatory Surgical Centers
- Specialty Clinics
- Others
Benign Prostatic Hyperplasia Treatment Surgical Treatment Segment Analysis
- Transurethral Resection of the Prostate (TURP)
- Transurethral Microwave Thermotherapy (TUMT)
- Transurethral Incision of the Prostate (TUIP)
Author's Detail
Anushka GoreResearch Associate at Cognitive Market Research
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the medical devices & consumables industry. She has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services. Her expertise in Market Research and business intelligence has equipped her with the skills necessary to analyze complex information and provide strategic recommendations.
In her current role, Anushka is a highly motivated and detail-oriented research analyst with a passion for uncovering valuable insights from data. She thrives in dynamic environments where her analytical abilities and research expertise can contribute to informed decision-making for businesses. Her collaborative approach facilitated effective communication of insights, fostering a data-driven culture within the organization.Anushka remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Benign Prostatic Hyperplasia Treatment Market is witnessing significant growth in the near future.
In 2023, the Drug Class segment accounted for noticeable share of global Benign Prostatic Hyperplasia Treatment Market and is projected to experience significant growth in the near future.
The Hospitals segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Abbott , Allergan plc and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Frequently Asked Questions (FAQs)
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Benign Prostatic Hyperplasia Treatment Market
Sources from Medical Devices & Consumables Industry
- http://www.trade.gov
- http://www.gov.uk
- http://www.fda.gov
- http://www.hhs.gov
- http://www.who.int
- http://www.bls.gov
- http://www.gao.gov
- http://www.ncbi.nlm.nih.gov
- http://www.healthcaredive.com
- http://www.weforum.org
- http://www.health.gov.za
- http://www.usaid.gov
- http://www.eumdr.com
- http://www.cdc.gov
- http://www.ama-assn.org
- http://www.washingtonpost.com
- http://www.ecfr.gov
- http://www.hbr.org
- http://www.worldbank.org
- http://www.commission.europa.eu
- http://www.cbi.eu
- http://www.unicef.org
- http://www.ecipe.org
- http://www.ema.europa.eu
Benign Prostatic Hyperplasia Treatment Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Type | Drug Class, Minimally Invasive Surgeries, Laser Therapy, Others |
| Application | Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others |
| Drug Treatment | Alpha-blockers, 5-Alpha-reductase Inhibitor (5-ARIs), Others |
| End-Use | Hospitals, Home Healthcare, Ambulatory Surgical Centers, Specialty Clinics, Others |
| Surgical Treatment | Transurethral Resection of the Prostate (TURP), Transurethral Microwave Thermotherapy (TUMT), Transurethral Incision of the Prostate (TUIP) |
| List of Competitors | Abbott, Astellas Pharma Inc, Allergan plc, GlaxoSmithKline plc, Eli Lilly, Boehringer Ingelheim GmbH, Asahi Kasei Corporation, Pfizer Inc, Boston Scientific Corporation, Sanofi, Merck & Co Inc, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Teleflex Incorporated, Endo International plc, Olympus Corporation |
This chapter will help you gain GLOBAL Market Analysis of Benign Prostatic Hyperplasia Treatment. Further deep in this chapter, you will be able to review Global Benign Prostatic Hyperplasia Treatment Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Benign Prostatic Hyperplasia Treatment Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Benign Prostatic Hyperplasia Treatment Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size By Region
-
-
1.3 Global Benign Prostatic Hyperplasia Treatment Market Size By Type 2019 -2031
-
1.3.1 Drug Class Market Size
-
1.3.2 Minimally Invasive Surgeries Market Size
-
1.3.3 Laser Therapy Market Size
-
1.3.4 Others Market Size
-
-
1.4 Global Benign Prostatic Hyperplasia Treatment Market Size By Application 2019 -2031
-
1.4.1 Hospitals Market Size
-
1.4.2 Ambulatory Surgical Centers Market Size
-
1.4.3 Specialty Clinics Market Size
-
1.4.4 Others Market Size
-
-
1.5 Global Benign Prostatic Hyperplasia Treatment Market Size By Drug Treatment 2019 -2031
-
1.5.1 Alpha-blockers Market Size
-
1.5.2 5-Alpha-reductase Inhibitor (5-ARIs) Market Size
-
1.5.3 Others Market Size
-
-
1.6 Global Benign Prostatic Hyperplasia Treatment Market Size By End-Use for 2019 -2031
-
1.6.1 Hospitals Market Size
-
1.6.2 Home Healthcare Market Size
-
1.6.3 Ambulatory Surgical Centers Market Size
-
1.6.4 Specialty Clinics Market Size
-
1.6.5 Others Market Size
-
-
1.7 Global Benign Prostatic Hyperplasia Treatment Market Size By Surgical Treatment for 2019 -2031
-
1.7.1 Transurethral Resection of the Prostate (TURP) Market Size
-
1.7.2 Transurethral Microwave Thermotherapy (TUMT) Market Size
-
1.7.3 Transurethral Incision of the Prostate (TUIP) Market Size
-
-
1.8 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.9 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.9.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.9.2 Global Market Revenue Split By Type
-
1.9.3 Global Market Revenue Split By Application
-
1.9.4 Global Market Revenue Split By Drug Treatment
-
1.9.5 Global Market Revenue Split By End-Use
-
1.9.6 Global Market Revenue Split By Surgical Treatment
-
1.9.7 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Benign Prostatic Hyperplasia Treatment Market Size 2019 - 2031
-
2.1.1 North America Benign Prostatic Hyperplasia Treatment Market Size By Country 2019 - 2031
-
2.1.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Type 2019 -2031
-
2.1.2.1 North America Drug Class Market Size
-
2.1.2.2 North America Minimally Invasive Surgeries Market Size
-
2.1.2.3 North America Laser Therapy Market Size
-
2.1.2.4 North America Others Market Size
-
-
2.1.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Application 2019 -2031
-
2.1.3.1 North America Hospitals Market Size
-
2.1.3.2 North America Ambulatory Surgical Centers Market Size
-
2.1.3.3 North America Specialty Clinics Market Size
-
2.1.3.4 North America Others Market Size
-
-
2.1.4 North America Benign Prostatic Hyperplasia Treatment Market Size by Drug Treatment 2019 -2031
-
2.1.4.1 North America Alpha-blockers Market Size
-
2.1.4.2 North America 5-Alpha-reductase Inhibitor (5-ARIs) Market Size
-
2.1.4.3 North America Others Market Size
-
-
2.1.5 North America Benign Prostatic Hyperplasia Treatment Market Size by End-Use 2019 -2031
-
2.1.5.1 North America Hospitals Market Size
-
2.1.5.2 North America Home Healthcare Market Size
-
2.1.5.3 North America Ambulatory Surgical Centers Market Size
-
2.1.5.4 North America Specialty Clinics Market Size
-
2.1.5.5 North America Others Market Size
-
-
2.1.6 North America Benign Prostatic Hyperplasia Treatment Market Size by Surgical Treatment 2019 -2031
-
2.1.6.1 North America Transurethral Resection of the Prostate (TURP) Market Size
-
2.1.6.2 North America Transurethral Microwave Thermotherapy (TUMT) Market Size
-
2.1.6.3 North America Transurethral Incision of the Prostate (TUIP) Market Size
-
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Benign Prostatic Hyperplasia Treatment Market Size 2019 - 2031
-
3.1.1 Europe Benign Prostatic Hyperplasia Treatment Market Size By Country 2019 - 2031
-
3.1.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type 2019 -2031
-
3.1.2.1 Europe Drug Class Market Size
-
3.1.2.2 Europe Minimally Invasive Surgeries Market Size
-
3.1.2.3 Europe Laser Therapy Market Size
-
3.1.2.4 Europe Others Market Size
-
-
3.1.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application 2019 -2031
-
3.1.3.1 Europe Hospitals Market Size
-
3.1.3.2 Europe Ambulatory Surgical Centers Market Size
-
3.1.3.3 Europe Specialty Clinics Market Size
-
3.1.3.4 Europe Others Market Size
-
-
3.1.4 Europe Benign Prostatic Hyperplasia Treatment Market Size by Drug Treatment 2019 -2031
-
3.1.4.1 Europe Alpha-blockers Market Size
-
3.1.4.2 Europe 5-Alpha-reductase Inhibitor (5-ARIs) Market Size
-
3.1.4.3 Europe Others Market Size
-
-
3.1.5 Europe Benign Prostatic Hyperplasia Treatment Market Size by End-Use 2019 -2031
-
3.1.5.1 Europe Hospitals Market Size
-
3.1.5.2 Europe Home Healthcare Market Size
-
3.1.5.3 Europe Ambulatory Surgical Centers Market Size
-
3.1.5.4 Europe Specialty Clinics Market Size
-
3.1.5.5 Europe Others Market Size
-
-
3.1.6 Europe Benign Prostatic Hyperplasia Treatment Market Size by Surgical Treatment 2019 -2031
-
3.1.6.1 Europe Transurethral Resection of the Prostate (TURP) Market Size
-
3.1.6.2 Europe Transurethral Microwave Thermotherapy (TUMT) Market Size
-
3.1.6.3 Europe Transurethral Incision of the Prostate (TUIP) Market Size
-
-
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size 2019 - 2031
-
4.1.1 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type 2019 -2031
-
4.1.2.1 Asia Pacific Drug Class Market Size
-
4.1.2.2 Asia Pacific Minimally Invasive Surgeries Market Size
-
4.1.2.3 Asia Pacific Laser Therapy Market Size
-
4.1.2.4 Asia Pacific Others Market Size
-
-
4.1.3 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application 2019 -2031
-
4.1.3.1 Asia Pacific Hospitals Market Size
-
4.1.3.2 Asia Pacific Ambulatory Surgical Centers Market Size
-
4.1.3.3 Asia Pacific Specialty Clinics Market Size
-
4.1.3.4 Asia Pacific Others Market Size
-
-
4.1.4 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by Drug Treatment 2019 -2031
-
4.1.4.1 Asia Pacific Alpha-blockers Market Size
-
4.1.4.2 Asia Pacific 5-Alpha-reductase Inhibitor (5-ARIs) Market Size
-
4.1.4.3 Asia Pacific Others Market Size
-
-
4.1.5 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by End-Use 2019 -2031
-
4.1.5.1 Asia Pacific Hospitals Market Size
-
4.1.5.2 Asia Pacific Home Healthcare Market Size
-
4.1.5.3 Asia Pacific Ambulatory Surgical Centers Market Size
-
4.1.5.4 Asia Pacific Specialty Clinics Market Size
-
4.1.5.5 Asia Pacific Others Market Size
-
-
4.1.6 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size by Surgical Treatment 2019 -2031
-
4.1.6.1 Asia Pacific Transurethral Resection of the Prostate (TURP) Market Size
-
4.1.6.2 Asia Pacific Transurethral Microwave Thermotherapy (TUMT) Market Size
-
4.1.6.3 Asia Pacific Transurethral Incision of the Prostate (TUIP) Market Size
-
-
Chapter 5 South America Market Analysis
-
5.1 South America Benign Prostatic Hyperplasia Treatment Market Size 2019 - 2031
-
5.1.1 South America Benign Prostatic Hyperplasia Treatment Market Size By Country 2019 - 2031
-
5.1.2 South America Benign Prostatic Hyperplasia Treatment Market Size by Type 2019 -2031
-
5.1.2.1 South America Drug Class Market Size
-
5.1.2.2 South America Minimally Invasive Surgeries Market Size
-
5.1.2.3 South America Laser Therapy Market Size
-
5.1.2.4 South America Others Market Size
-
-
5.1.3 South America Benign Prostatic Hyperplasia Treatment Market Size by Application 2019 -2031
-
5.1.3.1 South America Hospitals Market Size
-
5.1.3.2 South America Ambulatory Surgical Centers Market Size
-
5.1.3.3 South America Specialty Clinics Market Size
-
5.1.3.4 South America Others Market Size
-
-
5.1.4 South America Benign Prostatic Hyperplasia Treatment Market Size by Drug Treatment 2019 -2031
-
5.1.4.1 South America Alpha-blockers Market Size
-
5.1.4.2 South America 5-Alpha-reductase Inhibitor (5-ARIs) Market Size
-
5.1.4.3 South America Others Market Size
-
-
5.1.5 South America Benign Prostatic Hyperplasia Treatment Market Size by End-Use 2019 -2031
-
5.1.5.1 South America Hospitals Market Size
-
5.1.5.2 South America Home Healthcare Market Size
-
5.1.5.3 South America Ambulatory Surgical Centers Market Size
-
5.1.5.4 South America Specialty Clinics Market Size
-
5.1.5.5 South America Others Market Size
-
-
5.1.6 South America Benign Prostatic Hyperplasia Treatment Market Size by Surgical Treatment 2019 -2031
-
5.1.6.1 South America Transurethral Resection of the Prostate (TURP) Market Size
-
5.1.6.2 South America Transurethral Microwave Thermotherapy (TUMT) Market Size
-
5.1.6.3 South America Transurethral Incision of the Prostate (TUIP) Market Size
-
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by Type 2019 -2031
-
6.1.2.1 Middle East and Africa Drug Class Market Size
-
6.1.2.2 Middle East and Africa Minimally Invasive Surgeries Market Size
-
6.1.2.3 Middle East and Africa Laser Therapy Market Size
-
6.1.2.4 Middle East and Africa Others Market Size
-
-
6.1.3 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by Application 2019 -2031
-
6.1.3.1 Middle East and Africa Hospitals Market Size
-
6.1.3.2 Middle East and Africa Ambulatory Surgical Centers Market Size
-
6.1.3.3 Middle East and Africa Specialty Clinics Market Size
-
6.1.3.4 Middle East and Africa Others Market Size
-
-
6.1.4 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by Drug Treatment 2019 -2031
-
6.1.4.1 Middle East and Africa Alpha-blockers Market Size
-
6.1.4.2 Middle East and Africa 5-Alpha-reductase Inhibitor (5-ARIs) Market Size
-
6.1.4.3 Middle East and Africa Others Market Size
-
-
6.1.5 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by End-Use 2019 -2031
-
6.1.5.1 Middle East and Africa Hospitals Market Size
-
6.1.5.2 Middle East and Africa Home Healthcare Market Size
-
6.1.5.3 Middle East and Africa Ambulatory Surgical Centers Market Size
-
6.1.5.4 Middle East and Africa Specialty Clinics Market Size
-
6.1.5.5 Middle East and Africa Others Market Size
-
-
6.1.6 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size by Surgical Treatment 2019 -2031
-
6.1.6.1 Middle East and Africa Transurethral Resection of the Prostate (TURP) Market Size
-
6.1.6.2 Middle East and Africa Transurethral Microwave Thermotherapy (TUMT) Market Size
-
6.1.6.3 Middle East and Africa Transurethral Incision of the Prostate (TUIP) Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Benign Prostatic Hyperplasia Treatment Market Size by Type 2019 -2031
-
7.1.2 Country 1Benign Prostatic Hyperplasia Treatment Market Size by Application 2019 -2031
-
7.1.3 Country 1Benign Prostatic Hyperplasia Treatment Market Size by Drug Treatment 2019 -2031
-
7.1.4 Country 1Benign Prostatic Hyperplasia Treatment Market Size by End-Use 2019 -2031
-
7.1.5 Country 1Benign Prostatic Hyperplasia Treatment Market Size by Surgical Treatment 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Benign Prostatic Hyperplasia Treatment Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Abbott
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Astellas Pharma Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Allergan plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 GlaxoSmithKline plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Eli Lilly
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Boehringer Ingelheim GmbH
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Asahi Kasei Corporation
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Pfizer Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Boston Scientific Corporation
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Sanofi
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Merck & Co Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Teva Pharmaceutical Industries Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 GlaxoSmithKline PLC
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Teleflex Incorporated
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
8.2.15 Endo International plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.15.2 Business Overview
-
8.2.15.3 Financials (Subject to data availability)
-
8.2.15.4 Product Types Specification
-
8.2.15.5 Business Strategy
-
8.2.15.6 S.W.O.TAnalysis
-
-
8.2.16 Olympus Corporation
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.16.2 Business Overview
-
8.2.16.3 Financials (Subject to data availability)
-
8.2.16.4 Product Types Specification
-
8.2.16.5 Business Strategy
-
8.2.16.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2019 -2031
-
10.1 Drug Class
-
10.1.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Drug Class 2019 -2031
-
-
10.2 Minimally Invasive Surgeries
-
10.2.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Minimally Invasive Surgeries 2019 -2031
-
-
10.3 Laser Therapy
-
10.3.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Laser Therapy 2019 -2031
-
-
10.4 Others
-
10.4.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2019 -2031
-
11.1 Hospitals
-
11.1.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Hospitals 2019 - 2031
-
-
11.2 Ambulatory Surgical Centers
-
11.2.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Ambulatory Surgical Centers 2019 - 2031
-
-
11.3 Specialty Clinics
-
11.3.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Specialty Clinics 2019 - 2031
-
-
11.4 Others
-
11.4.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Others 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Drug Treatment Analysis 2019 -2031
-
12.1 Alpha-blockers
-
12.1.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Alpha-blockers 2019 -2031
-
-
12.2 5-Alpha-reductase Inhibitor (5-ARIs)
-
12.2.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by 5-Alpha-reductase Inhibitor (5-ARIs) 2019 -2031
-
-
12.3 Others
-
12.3.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by End-Use Analysis 2019 -2031
-
13.1 Hospitals
-
13.1.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Hospitals 2019 -2031
-
-
13.2 Home Healthcare
-
13.2.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Home Healthcare 2019 -2031
-
-
13.3 Ambulatory Surgical Centers
-
13.3.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Ambulatory Surgical Centers 2019 -2031
-
-
13.4 Specialty Clinics
-
13.4.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Specialty Clinics 2019 -2031
-
-
13.5 Others
-
13.5.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 14 Market Split by Surgical Treatment Analysis 2019 -2031
-
14.1 Transurethral Resection of the Prostate (TURP)
-
14.1.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Transurethral Resection of the Prostate (TURP) 2019 -2031
-
-
14.2 Transurethral Microwave Thermotherapy (TUMT)
-
14.2.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Transurethral Microwave Thermotherapy (TUMT) 2019 -2031
-
-
14.3 Transurethral Incision of the Prostate (TUIP)
-
14.3.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Size and Share by Transurethral Incision of the Prostate (TUIP) 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Benign Prostatic Hyperplasia Treatment market
Chapter 15 Research Findings
-
15.1 Key Takeaways
-
15.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
15.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Anushka Gore and Team
- 1.1 Benign Prostatic Hyperplasia Treatment Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Benign Prostatic Hyperplasia Treatment Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Benign Prostatic Hyperplasia Treatment Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Benign Prostatic Hyperplasia Treatment Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Benign Prostatic Hyperplasia Treatment Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Benign Prostatic Hyperplasia Treatment Market
Key Questions Answered By Benign Prostatic Hyperplasia Treatment Market Report 2024
| Why Drug Class have a significant impact on Benign Prostatic Hyperplasia Treatment market? |
| What are the key factors affecting the Drug Class and Minimally Invasive Surgeries of Benign Prostatic Hyperplasia Treatment Market? |
| What is the CAGR/Growth Rate of Hospitals during the forecast period? |
| By type, which segment accounted for largest share of the global Benign Prostatic Hyperplasia Treatment Market? |
| Which region is expected to dominate the global Benign Prostatic Hyperplasia Treatment Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
